A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03573323 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1027

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Ixekizumab
DRUG: Guselkumab
DRUG: Placebo

Sponsor

Eli Lilly and Company